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resumo 
 
 
Nos últimos anos tem sido discutido em que medida são 
fornecidos dados suficientes para estimar o valor clínico do 
medicamento durante o processo de aprovação e autorização de 
introdução no mercado (AIM). Apesar dos ensaios clínicos 
randomizados (ECR) possuírem extrema validade interna na 
avaliação da segurança e eficácia de novos produtos, não 
permitem a extrapolação dos dados de eficácia para a vida real 
(efetividade).  
Alguns peritos têm discutido o potencial uso dos dados recolhidos 
na vida real (DVR) na contribuição de uma avaliação mais 
robusta de produtos e resultados em saúde. 
Os avanços nas tecnologias da informação permitem recolher, 
partilhar, analisar e utilizar grandes quantidades de informação a 
um custo relativamente baixo. Neste contexto, os DVR podem ser 
usados em conjunto com ECR e outros dados médicos para 
proporcionar perspectivas sobre resultados clínicos reais. Se 
esses dados e metodologias puderem ser canalizados para a pré-
AIM, os titulares serão capazes de direccionar o desenvolvimento 
de medicamentos para áreas onde o valor é susceptível de ser 
elevado para os doentes e sistemas de saúde. Assim, as 
agências regulamentares e de avaliação de tecnologias da saúde 
terão informação suficiente para tomar decisões devidamente 
fundamentadas sobre a eficácia relativa de novas intervenções 
em saúde. 
 
O principal objetivo desta tese é promover uma análise da 
utilidade dos DVR, como criadores de valor, em todas as fases de 
desenvolvimento de medicamentos e discutir o papel-chave de 
todas as partes interessadas no uso de DVR. 
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abstract 
 
It has long been discussed to which extend the licensing 
procedure should assure the availability of sufficient data to 
assess the clinical value of a new dug at the time of marketing 
introduction. Despite the high internal validity of randomised 
clinical trials (RCTs) generated evidence and its ability to robustly 
indicate the safety and efficacy of new products, it falls short of 
allowing for extrapolation from efficacy to clinical effectiveness.  
A number of analysts and academics have signalled the potential 
of real-world data (RWD) to contribute to improved health 
products and outcomes. Advances in computing allow collecting, 
share, analyse and use large quantities of data routinely at a 
relatively low cost. In this context, RWD can be used in 
conjunction with RCTs and other medical data to provide insights 
into real-world clinical outcomes. If such data and methodologies 
could be harnessed in pre-authorisation drug development, drug 
manufactures would be able to direct drug development to areas 
where value is likely to be highest for patients and health systems. 
In addition, regulatory and Heath Technology Assessment (HTA) 
agencies would be able to make better-informed decisions on 
relative effectiveness of new health interventions.  
 
The main goal of this thesis is to analyse the usefulness of RWD 
collection, as creator of value, in all drug development phases and 
discuss the key role of all stakeholders in use of RWD.  
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1. INTRODUCTION 
 
During pre-authorisation drug development phases, pharmaceutical manufacturers invest 
considerable time and funds in conducting phase III clinical studies to provide robust data 
on the safety and efficacy of their products. Such studies are designed as randomised 
clinical trials (RCT’s) which typically have strict inclusion and exclusion criteria for trial 
subjects and within which experimental products are often conventionally compared to a 
placebo arm, rather than an active treatment. Consequently, experimental products 
being presented for marketing authorisation are accompanied by data that provides 
safety and efficacy data with very high internal validity but whose results are perhaps not 
easily generalised to the broader, more heterogeneous clinical population
1
. Medicine use 
in clinical practice frequently differs widely from the (pre-approval) clinical trial settings. 
Patients are diverse, with varying disease histories and co-medications and they do not 
always comply with instructions and persist with treatment over time
2
. 
Selective ciclo-oxigenase-2 (COX-2) inhibitors provide an example of the challenges in 
generalising evidence from authorisation RCTs to routine clinical practice. The main RCTs 
of rofecoxib and celecoxib that were used to obtain the marketing authorisation 
restricted study eligibility to patients with severe osteoarthritis or rheumatoid arthritis 
who were expected to use the study drug daily for the duration of the studies (six to nine 
months)
2–4
. However, an analysis found that the large majority of patients using selective 
COX-2 inhibitors in routine clinical practice would not have been eligible for these main 
RCTs as they did not have severe osteoarthritis or rheumatoid arthritis and this not use 
these medicines every day for a number of months. The results of authorisation RCTs are, 
therefore, not always generalizable to patients in routine clinical practice
2,5,6
. 
Authorisation RCTs typically assess the efficacy of a medicine, that is, the effects under 
ideal circumstances. On the other hand, effectiveness concerns the effects of a medicine 
under routine clinical circumstances. There are various reasons for differences between 
efficacy and effectiveness. One reason leading to these differences is the adherence of 
patients to the medication and the recommended dosage instructions. Another reason 
for the discrepancy between efficacy and effectiveness are differences in dosages. A 
challenge in the generalizability of evidence from RCTs to real life concerns patients who 
were not eligible for the RCTs
2
. 
It has long been discussed to which extend the licensing procedure should assure the 
availability of sufficient data to assess the therapeutic value of a new drug at the time of 
market introduction
7
. Regulatory agencies are those faced with the issue of making 
decisions based upon data with inherent uncertainties on the aspects of real-world 
effectiveness. Similarly, health technology assessment (HTA) agencies and healthcare 
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payers often refer to RCT-generated evidence available at the time of initial authorisation 
to pass judgement on the relative effectiveness of the new products. Thus, in the light of 
making decisions with high uncertainties on post-marketing performance of new drugs, 
regulatory and HTA agencies alike increasingly require applicants to fulfil post-marketing 
data collection commitments (e.g. post-marketing safety/efficacy studies, risk-sharing 
agreements). Such data is better suited to answering questions on clinical safety and 
effectiveness, owing to the fact that they are collected from patients representing routine 
practice
1
.  
A number of analysts and academics have signalled the potential of real-world data 
(RWD) to contribute to improved health products and outcomes. Advances in computing 
allow collecting, share, analyse and use large quantities of data routinely at a relatively 
low cost – as never before. The increased use of new technologies in the healthcare 
sector has changed the ways in which patient level information are collected, stored and 
used
8
. If such data and methodologies could be harnessed in pre-authorisation drug 
development, drug manufacturers would be able to direct drug development to areas 
where value is likely to be highest for patients and health systems
1
. 
A range of stakeholders in health research, innovation and care delivery hope that the 
combination of RCT data and RWD can be used to help develop more targeted drugs and 
to encourage better use of those drugs by clinicians and patients. Data relating to patient 
experience in using drugs and to the contexts and settings in which drugs are used could 
potentially play a role in the way that trials are designed and conducted, the processes of 
drug registration and post-marketing benefit risk assessment, as well as create novel 
incentives for open health research. In the context of the severe cost and productivity 
challenges that health researchers and innovators have experienced in recent years, the 
prospect of data and mechanisms that could improve efficiency at multiple levels of the 
health research ecosystem without the cost of clinical trials is welcomed by many
8
.  
 
The main goal of this thesis is to analyse the usefulness of RWD collection, as creator of 
value, in all drug development phases and discuss the key role of all stakeholders in use of 
RWD.  
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2. DEFINITION OF REAL-WORLD DATA  
 
In 2007, the International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) created an International Task Force to develop a framework to assist health-care 
decision-makers in dealing with RWD. From the outset, the Task Force grappled with the 
definition and appropriate characterization of RWD. It seemed self-evident that RW 
outcomes data should come from RW situations. Part of the Task Force’s charge was to 
consider uses and limitations of evidence not obtained from RCTs. On the other hand, it 
was also clear that decision-making is a highly integrative process of synthesizing 
information from different sources—both “laboratory” and real-world. They settled on a 
definition that reflects data used for decision-making that are not collected in 
conventional RCTs (for methodological, ethical or other reasons)
9,10
. This is not to say that 
data from RCTs are irrelevant or not used by decision-makers; indeed, they remain the 
critical foundation for almost all initial coverage and payment decisions
9
. 
In the last years some alterations have been made in the definition of RWD, created in 
the Task Force. In 2014 RAND Europe adopted the following explanation: 
RWD is any data not collected in conventional randomised controlled trials. It includes 
data from existing secondary sources (e.g. databases of national health services) and the 
collection of new data (e.g. pragmatic trials; observational studies), both retrospectively 
and prospectively
8,11
. 
 
The Task Force also deliberated distinctions between the terms RWD and real-world 
evidence (RWE). Evidence is generated according to a research plan and interpreted 
accordingly, whereas data is one component of the research plan (Figure 1). Evidence is 
shaped, while data simply are raw materials and alone are non-informative
9
. In general, 
RWE is what happens to data. Building the evidentiary portfolio requires the systematic 
unbiased collection of data. The validity of the evidence is dependent on the accuracy of 
the data and the appropriate organization to allow interpretation, analysis, and 
conclusions
12
. Simply stated, RWE is the application of RWD to derive insights that can be 
generalized to usual care settings
13
. 
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Figure 1. RWE is generated by applying a question or testing a hypothesis using RWD and 
applying analytical techniques set out in the study design
14
. 
 
Real world studies (RWS) was defined as all clinical studies investigating health 
interventions whose design does not follow the design of a randomised controlled clinical 
trial and aims to reflect health intervention effectiveness in routine clinical practice. RWS 
do not typically include randomisation of trial subjects, but there are exceptions (e.g. 
pragmatic clinical trials). RWS include, but are not limited to, the following: pragmatic 
clinical trials, non-interventional/ observational studies, drug utilisation studies, post-
authorisation efficacy/safety studies. RWS, by definition, generate RWD, which can 
subsequently be analysed and/or synthesised to produce RWE
1,15
.   
The design used in an RWS needs to have rigour appropriate to the disciplines it is drawn 
from. Table 1 sets out the possible elements of an RWS.  
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Table 1. The design of RWS
14
. 
Element of RWS Design of an observational study 
Subjects 
• Includes those eligible for care from the health system 
• Clinical topics where case finding and outcomes are measured using routine 
data 
• Large number of cases 
• Case definition will be that of usual practice 
• Wide range of other therapies and co-morbidities 
• Few inclusion/exclusion criteria 
Setting 
• Routine care 
• Range of treatment pathways 
• Comprehensive use of computerised medical records, across the care 
pathway 
• Need to infer meaning from ‘messy’ routine data 
Intervention/exposure 
• Prospective (including pragmatic RCTs) and retrospective studies are possible 
• Open label/neither clinician nor patient will be blinded 
• May be over a long period of time 
• That delivered as part of usual care/generally no additional visits 
• Standard patterns of adherence, no attempts to change beyond those that 
are part of routine care 
Outcome measure 
• Defined from routine data 
• Loss to follow-up of those who move out of area/out of system 
• Avoids recall bias 
• Can include health economic impact 
Comparator group 
• Differences in exposure 
• From different localities 
• Before and after 
• Stepped introduction of programme 
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3. CHARACTERIZATION OF REAL-WORLD DATA 
 
There are several ways in which one might characterize RWD. One is by type of outcome: 
clinical, economic, and patient-reported outcomes (PRO). An advantage of this approach 
is that it corresponds to the way in which many decision makers conceive of data. A 
downside is that it provides broad categories, each of which combines many types and 
sources of evidence
9
. 
A second characterization involves traditional hierarchies of evidence, which rank 
evidence according to the strength of the research design. Traditionally, RCT data has 
been regarded as being at the top of the hierarchy of evidence quality, followed by data 
from non-randomised intervention studies, followed by epidemiological studies and so 
forth. Evidence hierarchies provide a useful ranking based on the rigor of the research 
design; however, they do not provide a complete picture of RWD. The results from many 
RCTs are not generalizable to a broader population. Conversely, a well-conducted 
observational study may prove highly useful in certain situations provided that potential 
biases have been adequately addressed. Indeed, there has been recognition among key 
opinion leaders that RWD have a place alongside RCT data providing valuable evidence of 
use in clinical practice that cannot be gained from RCTs
9,16
.  
Finally, one might consider RWD by types of data sources. The value of this classification 
is that it identifies tangible sources of information. A potential drawback is that it 
represents a simplification that does not capture important design issues within each 
source of evidence
9
.  
Each of the three characterizations provides a different perspective on RWD. Collectively, 
they provide a useful portrait of the strengths, weaknesses, and complexities inherent in 
the topic
9
. 
 
3.1 TYPES OF OUTCOMES 
Clinical outcomes: Clinical outcomes include biological measures of morbidity (e.g., blood 
pressure, cholesterol level, symptoms, and side effects) and mortality. Clinical outcomes 
include both surrogate (intermediate) and long-term measures
9
.  
Much of the data collected in phase III registration trials involves clinical outcomes. 
Clinical outcome data are also found in many other sources, such as patient registries or 
observational databases
9
. 
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Economic outcomes: “Economic outcomes” are narrowly defined here to include 
estimates of medical and non-medical resource utilization and their associated costs. 
Such data are used to project the expected cost of an intervention in the real world-e.g., 
in the numerator of a cost-effectiveness ratio. Many sources of RWD are useful in 
providing use and cost information
9
.  
 
PROs/quality of life (QoL). PRO is the term adopted internationally to encompass any 
report coming directly from patients about a health condition and its treatment, including 
symptoms, functional status, health-related quality of life (HRQoL), treatment 
satisfaction, preference and adherence
9
.  
Over recent years, the importance of the patient perspective has risen to the top of the 
agenda. Patients’ views are key to two aspects of RWD. First, systematically recording and 
evaluating patients’ experiences of their health care, including their satisfaction with the 
delivery of services, is increasingly recognised as relevant to assessments of the quality of 
health care. Capturing patient feedback has been recognised as a significant driver for 
improved services, essential for service design and delivery, monitoring improvements 
and key to ensuring high quality care for all
9,16
. 
Second, there is increasing recognition that patients’ views of their own health, measured 
using validated and reliable survey instruments (Patient Reported Outcome measures – 
PROs, or PROMs) provide an important and highly relevant way of assessing the effects of 
treatment, which are complementary to conventional clinical endpoints. The researchers 
have long recognized that self-reports of outcomes related to disease, injury, treatment 
or policy are important, because they provide the only direct voice that an individual has 
in the health decision making process
9,16
. 
As people live longer with chronic conditions, PROs have become increasingly important 
to pharmaceutical manufacturers in assessing the impact of emerging chronic treatments 
and in communicating the benefits of these drug treatments in label and promotional 
claims
9
.  
 
3.2 EVIDENCE HIERARCHIES  
Historically, evidence hierarchies have been linked to “evidence-based medicine” (EBM). 
The thrust of the EBM movement is to ground clinical practice in rigorous research. EBM 
proponents emphasize that traditional medical practice incorporated local practices and 
expert opinion that were not tested in controlled studies. They stress the need for clinical 
researchers to document all study protocols, utilize appropriate analytical techniques, 
and strive for internal consistency. Studies are to be considered externally valid when 
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findings are generalizable beyond local clinical practices. A scientific body of evidence 
became reliable and generalizable when similar results were reported by different 
researchers across a range of study designs and patient populations. For these reasons, 
RCTs were placed at the top of the evidence hierarchy
9
.  
In accordance with Committee on Environment, Public Health and Food Safety (ENVI) of 
the European Parliament, evidence for the medical-therapeutic evaluation is assessed 
according to six types of evidence. The first group (prospective, double-blind, 
randomised-control studies representing a large population, or meta-studies of such 
studies) are assigned the highest level of validity. They are followed (in descending order) 
by 2.systematic reviews; 3.randomised-control studies with less data; 4.non-randomised 
and uncontrolled studies; 5.consensus judgements of an expert committee; 6. statements 
of experts
17
. 
Decision makers, however, quickly recognized the impracticality of basing all of medicine 
on RCTs. For one thing, RCTs are expensive. For another, even the best RCT reflects a 
limited controlled experiment that may not generalize to populations, settings, or 
conditions not reflected in the trial. The need for non-RCT information became apparent, 
raising the question of how to grade information that by definition was of “poorer 
quality?” 
9
. 
 
3.3 DATA SOURCES 
RWD can also be categorized by type of data source. The ISPOR Task Force defined six 
such sources: 1) supplements to traditional registration RCTs; 2) pragmatic clinical trials 
(also known as large simple trials or practical clinical trials); 3) registry studies; 4) claims 
databases/administrative data; 5) health surveys; and 6) electronic health records and 
medical chart reviews
9
.  
 
Supplements to RCTs. To provide additional data alongside standard clinically focused 
RCTs, researchers often gather information on variables such as PROs, medical resource 
use, and costs. Such efforts can add valuable evidence on treatment patterns for common 
events, e.g., such as the doses of drugs used to treat rejection in kidney transplantation
9
. 
Limitations to such data are also well known: their primary aim is to measure a key clinical 
efficacy endpoint in a carefully limited population and clinical setting. Furthermore, trials 
are not usually powered statistically to measure precisely the probability of rare adverse 
or other events and hence are of limited use in measuring the associated resource 
utilization and costs. RCTs are generally conducted over a shorter time frame than what is 
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relevant for determining the overall clinical and economic impact of an intervention, and 
resource use is often protocol-driven
9
. 
 
Pragmatic clinical trials. Large simple trials (also called practical or pragmatic clinical 
trials) involve prospective, randomised assignment but aimed at larger more diverse real-
world population. Practical clinical trials have the important strength of randomisation, 
which minimizes bias in the estimation of treatment effects. These trials are by design 
larger than conventional RCTs. For this reason, they are more likely to have sufficient 
power to capture significant differences in key outcomes of interest, such as 
hospitalizations
9
.  
Because the focus is on obtaining policy-relevant outcomes, costs and cost-effectiveness 
are more likely to be central endpoints, and the results can be more readily generalized to 
the relevant treatment population than those obtained from conventional RCTs: costs are 
less likely to reflect protocol-driven health care use; well-documented variations in 
resource use across various ethnic, racial, age groups and genders can be better captured 
by opening the trial to a more diverse population; people more at risk for adverse events 
are less likely to be excluded from the trial, and the related economic effects are more 
likely to be captured; and resource use and costs are more likely to reflect those observed 
in community-based settings where most people obtain their care, especially since study 
drugs in phase III trials are generally provided for free
9
.  
However, the large size of a practical clinical trial increases the cost of data collection and 
raises some concerns about the quality of data collected. Costs are increased not only 
because a larger number of patients are enrolled, but also because a larger number of 
settings are involved. Some of the issues raised by economic data collection within 
practical clinical trials are: identification of where subjects receive care may be more 
difficult (less in a closed system); data collection systems of community-based settings 
may be less sophisticated than those of academic settings (for example, more likely to use 
paper rather than electronic records, thus increasing the likelihood of data entry errors); 
there is more likely to be a lack of standardization in financial and billing systems across 
different settings of care; and more study coordinators will be involved in the data 
collection effort
9
.  
 
Registry studies. Registries are prospective, observational cohort studies of patients who 
have a particular disease and/or are receiving a particular treatment or intervention. They 
can be used for understanding natural history, assessing or monitoring real-world safety 
and effectiveness, assessing quality of care and provider performance, and assessing cost-
effectiveness
9
. 
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Registries involve prospective data collection of clinical, economic, and PRO information, 
and are increasingly relying on real-time data capture. They typically include a larger and 
more diverse group of patients than what is generally studied in phase III RCTs; therefore, 
they better reflect real-world patients, management practices, and outcomes. Patients 
are often followed over a longer timeframe, allowing for an assessment of longer-term 
outcomes. Most registries have very few, if any, required visits, evaluations, or 
procedures; therefore, the treatment patterns reflect the everyday clinical decision-
making that is most relevant to providers and payers. Disease registries enable providers 
and payers to gain insight into the most cost-effective treatment approaches
9
.  
Because registries do not involve random assignment to treatment, care must be taken in 
analysing and interpreting the results due to the inherent limitations of observational 
studies. There is no guarantee that patient groupings are comparable: therefore, 
registries may not be suitable to test hypotheses, but are useful to generate them. 
Furthermore, there are limitations in terms of the amount of data that can be collected, 
and because visit schedules are not required, data cannot necessarily be obtained at fixed 
intervals. Registries sometimes include study sites that are not experienced in conducting 
research, and without appropriate oversight, data integrity could be in question. 
However, the use of real-time data capture is likely to improve data monitoring and 
integrity. Registries are, in some cases, established to collect post-marketing safety data, 
either in response to specific safety concerns or to fulfil regulatory obligations established 
as a condition of marketing approval
9
.  
 
Claims databases. Administrative data (typically retrospective or real time, if possible) are 
collected primarily for reimbursement, but contain some clinical diagnosis and procedure 
use with detailed information on charges. Claims databases lend themselves to 
retrospective longitudinal and cross-sectional analyses of clinical and economic outcomes 
at patient, group, or population levels. Such analyses can be performed at low overall cost 
and in a short period of time. Given the sheer size of claims databases, researchers can 
identify outcomes of patients with rare events more easily, assess economic impact of 
various interventions, and gain insight into possible association between interventions 
and outcomes
9
.  
Administrative claims databases can prove very useful in measuring resource use and 
costs, provided some basic principles are met. A clear research question needs to be 
defined and addressed by an appropriate design from a well-defined perspective. 
Available statistical tools can be used to help control for some of the potential biases. 
Methods and results should be reported in a clear and transparent fashion, so that other 
researchers are able to understand and reproduce the analyses
9
.  
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Beyond challenges posed by privacy issues, the validity of retrospective claims database 
analyses has been challenged on several fronts: data quality (missing data, coding errors- 
whether random or “intended”-and the lack of comprehensive data across health care 
settings); the lack of or very limited clinical information on inpatient stays, health 
outcomes, health status, and symptoms; limited validation; absence of a population 
denominator; and the lack of distinction between costs and charges. Of course, the large 
size of these databases may be able to overcome the issue of missing data if they are 
missing at random. If data quality can be ascertained and privacy issues addressed, then 
treatment selection bias in the sample is the most common and challenging 
methodological issue. Estimates of the effects and costs can be biased due to a 
correlation between unobserved factors associated with treatment selection and 
outcomes, such as baseline health status
9
.  
 
Health surveys. Health surveys are designed to collect descriptions of health status and 
well-being, health care utilization, treatment patterns, and health care expenditures from 
patients, providers, or individuals in the general population. Health surveys typically 
collect information on representative individuals in the target population, whether 
patients, physicians or general population, and are methodologically rigorous, for 
example, relying on complex sample survey designs. With these designs, surveys can 
provide information about all members of the target population, not just those who are 
participating in a given RCT, or members of a particular health plan. As a result, health 
survey data can make unique contributions about generalizability of treatments and their 
impacts and about use of and expenditures for health services
9
. 
 
Electronic health records (EHRs) and medical chart review. Finally, it was noted 
electronic health records (and other technologies capturing real-time clinical treatment 
and outcomes) are important sources for RWD for a wide range of clinical settings 
throughout the world. The expansion of electronic data capture is essentially lowering the 
cost of the medical chart reviews that have been widely used in the past to produce 
specific information on the RW use of specific tests or drugs for particular conditions. 
EHRs—such as the UK General Practice Research Database-contain more detailed, 
longitudinal information including disease-specific symptoms at the personal level and 
should greatly expand the use of this type of information. However, transforming the 
information for research purposes requires high-end statistical analysis tools and remains 
a challenge
9
. 
These 6 data sources are echoed in publications from Quintiles and IMS Consulting. Very 
similar lists are suggested by National Pharmaceutical Council (NPC) and National 
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Information Center on Health Services Research and Health Care Technology (NICHSR) in 
the USA (Figure 2)
18
. 
 
Figure 2. Venn diagram to illustrate the areas of agreement in the definition of real 
world studies across international organisations (ISPOR, NPC and NICHSR)
18
.  
a)
Collection of PRO; resource use and cost data EHR  
 
Very few bodies appear to employ a narrower definition of RWS than that from the ISPOR 
task force. The European Commission include the concept of no randomisation in their 
definition; although this is in reference to observational research, as opposed to RWD 
specifically (these terms are often used interchangeably). By deduction, this would 
exclude pragmatic studies from their definition. ISPOR’s definition of observational 
research is more vague on this point, stating that care is not typically a result of 
randomisation (or other forms of patient assignment), presumably to allow the inclusion 
of pragmatic studies. The classification of pragmatic studies as a method of RWD 
collection could potentially be a point of contention. The ISPOR task force acknowledge 
that whether they are strictly RWS is open to debate. On the other hand, many 
international bodies group include them in their definition of RWS
18
: 
 NPC, USA 
 NICHSR1, USA 
- The NICHSR appear to differentiate between large simple trials and pragmatic 
clinical trials, unlike other organisations which used the terms interchangeably. But 
they explain that some large simple trials are also pragmatic trials. 
                                                          
1
 The NICHSR are part of the US National Institutes of Health (NIH) and were set up at the National Library of Medicine 
to improve ". the collection, storage, analysis, retrieval, and dissemination of information on health services research, 
clinical practice guidelines, and on health care technology, including the assessment of such technology." 
Registries
Claims data
EHR
Chart review
Pragmatic studies
Supplements 
to RCTsa
Health surveys
NPC
NICHSRISPOR
   
13 
 
- Large simple trials: retain the methodological strengths of prospective, randomised 
design, but use large numbers of patients, more flexible patient entry criteria and 
multiple study sites to generate effectiveness data and improve external validity.  
Fewer types of data may be collected for each patient, easing participation by 
patients and clinicians.   
- Pragmatic trials are a related group of trial designs whose main attributes include: 
comparison of clinically relevant alternative interventions, a diverse population of 
study participants, participants recruited from heterogeneous practice settings, and 
data collection on a broad range of health outcomes.   
 Patient-centred outcomes research institute (PCORI), USA 
- PCORI implies that pragmatic studies are categorised as RWS through its 
announcement of a new research funding initiative for pragmatic trials ("More 
Support for Bigger, Longer Real-World Trials"). 
 Medicines and Healthcare products Regulatory Agency (MHRA), UK 
- It could be inferred from the MHRA business strategies that pragmatic studies 
(utilising (Electronic health records - EHR) are considered to produce RWD. 
 Farr Institute, UK 
- It could be inferred from the programme for their industry forum meeting that 
pragmatic trials are included in their consideration of RWD collection. 
 
To revisit the concept of observational research - it seems the main defining feature of 
observational research, common across publications, is that care is not dictated or 
mandated. That is, the investigator does not interfere with choice of the prescribed 
health intervention such that interventions are prescribed in the usual manner in 
accordance with the terms of the marketing authorisation. But it is not that simple, as 
there are inconsistencies internally regarding the definition of an intervention.  
Depending on local regulations, for example, blood tests and patient questionnaires may 
be considered interventional in some countries (particularly in Europe) but not in 
others
18
. 
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4. THE ADVANTAGES OF REAL-WORLD DATA  VS. RANDOMISED CLINICAL TRIALS  DATA 
 
RCTs are well recognized as the “gold standard” for evaluating treatment outcomes. They 
are designed to test a therapeutic hypothesis under optimal conditions in the absence of 
confounding factors: highly selected patients, optimal management conditions, and ideal 
settings; nevertheless their comprehensive exclusion criteria may produce studies in a 
narrow segment of the population only, leading to results with limited external validity. 
Groups which are often under-represented in RCTs include women, children, the very 
elderly ethnic minorities and those with multiple co-morbidities
16,19
. Thus, they provide 
information on efficacy under conditions very different from real life
19
. In other words, 
RCT findings are limited in the extent to which they can be extrapoled to reflect the 
treatment effects achievable at the population level (Figure 3). Outside the strictly 
controlled environment of the classical RCT, many factors can interfere with a therapeutic 
option’s potential efficacy
11
. 
Figure 3. Scope of RWS vs. RCTs in the population
16
. 
 
In contrast, RWS assess effectiveness in large unselected populations, which include 
patients with comorbidities
20
. RWS have been described in a variety of ways. The 
European Working Group on Relative Effectiveness has defined RWS as a way to analyse 
medical data collected under real life conditions. RWS consider a more contextualised 
endpoint, this takes account of the constraints on outcomes imposed in normal clinical 
care by such factors as unavailability of diagnostic or monitoring tests, poor adherence to 
treatment and non-standard dosing or administration. In essence, they are conducted in 
everyday settings, and for this reason, they provide insights into the real life effectiveness 
of a medical condition/intervention
16,19
(Table 2).  
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Table 2. Main differences between randomised clinical trials and observational research
21
. 
 
At variance with RCTs, pragmatic trials are conducted in a routine care setting with 
heterogeneous patient populations and prolonged durations, which increase the 
likelihood of obtaining conclusions relevant to clinical practice
19
. Purely observational 
studies, which involve no artefact of intervention, may best reflect this real-world 
experience but are, themselves, burdened with methodological peculiarities
21
. 
The limitations of RWS are often intrinsically associated with their characteristic design
19
. 
Whether or not a study realistically represents real-life conditions can be unclear. A trial 
might involve intensive patient follow-up, yet include a broad population fairly 
representative of the true treated population. Conversely, an observational study can 
focus on outcomes in a highly-selected patient population, yet involve no clinical 
intervention beyond usual care. The challenge is to recognise and describe which 
elements of a study represent real-life, and to find a unified way of presenting them. 
Roche et al., (2013) proposed a framework to classify different studies by design to assist 
those involved in the use conduct, review, and quality appraisal of therapeutic research, 
including patients, clinicians, policy-makers, and guideline developers (Figure 4)
22
. 
Randomised clinical trial Observational studies and registries 
Conducted to demonstrate efficacy and main 
safety profile of drug. 
Conducted to demonstrate effectiveness of drug under 
conditions of routine clinical care and confirm safety profile. 
Evaluate especially rare events and potential safety signals. 
Randomisation takes care of confounding 
factors (creates structural homogeneity). 
Design and statistical analysis strategy should minimize influence 
of confounding. 
Relatively short-term duration. 
Allow long-term follow-up and investigation of chronic use. 
Investigate long-term safety. 
Relatively small numbers with limited ability 
to detect safety issues with low incidence. 
Allows large sample size. 
Very restricted (homogeneous) patient 
population (low external validity). 
Conducted in real-world patients with broad age range and 
comorbidity (good external validity). 
Relatively low risk population for concurrent 
events. 
Relatively high risk population for concurrent events. 
Very good compliance as strict controlling and 
monitoring. 
Unclear compliance – often only information about prescription – 
not actual adherence. 
Usually one comparator (standard of care) or 
placebo. 
Allows comparison of different treatments and different 
treatment practices across populations. 
Strictly protocol driven. 
Less influence on data quality and time points of data collection – 
driven by usual care practice. Allows investigation of unintended 
exposure (e.g. during pregnancy). 
Often 100% source monitoring – excellent 
quality. 
Restricted means of source monitoring. 
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Figure 4.  A conceptual framework for therapeutic research
22
. 
Studies are described in terms of their design or ecology of care (x-axis) and their population characteristics 
(y-axis), with each axis representing a continuum. 
 
The framework classifies studies within a two dimensional real-life space bound by the 
study population (y-axis) and ecology of care (x-axis). The ecology of care axis categorises 
study interventions along a continuous scale (from highly-controlled efficacy RCT 
management and follow-up, at one end, to usual care at the other). The label between 
the two-pragmatically controlled—refers to controlled trials that are designed to 
resemble usual care in terms of intensity of follow-up and in terms of reference, studied, 
and concomitant treatments. The population axis categorises study populations along a 
continuum from those with a confirmed, pure diagnosis (denoting a highly-selected 
population with no interfering comorbidities, modifying treatments or risk factors) 
through to a so-called managed-as population (ie, managed as having a condition with or 
without a confirmed diagnosis). Neither of these characteristics on its own is sufficient to 
describe the validity or utility of clinical study results to real life
22
. 
Figure 4 illustrates typical positions of the most common study designs, but studies can 
be located anywhere within the framework depending on the specifics of their design. 
The origin of the two axes corresponds to trials with the highest internal and lowest 
external validity. The further a trial is positioned from the origin, the greater are its real-
life attributes, conditioning its generalizability
22
.  
Comprehensive assessment of therapeutic strategies requires evaluation of both their 
efficacy under optimum conditions (high internal validity) and effectiveness in real-life 
populations and situations (high external validity). To ascertain the relevance of study 
findings to target populations and clinical decision making, studies must first be well 
   
17 
 
described in terms of patient selection and ecology of care. Only then can appropriate 
quality assessments be selected and undertaken
22
. 
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5. DECISIONS IMPACTED BY REAL-WORLD DATA   
 
RWD currently plays a prominent role in several contexts of the product lifecycle. It 
features during drug development (e.g. to determine natural history, define 
subpopulations with better benefit-risk profiles, inform the design of pivotal trials); within 
drug regulation activities (e.g. fulfilment of post-marketing commitments, conditional 
marketing authorisations and adaptive pathways, examining drug utilization and 
adherence to approved indications); and during reimbursement discussions (e.g. as inputs 
for resource use and effectiveness data for pharmacoeconomic modelling, relative 
effectiveness assessment, and marketing access agreements)
1,23
 (Figure 5) (Table 3). 
Moreover, the assessment of the value of medicines and treatments in real-world settings 
may be made less resource intensive with RWD-based methodologies
8
.  
 
Figure 5. Examples of pre-launch and post-launch evidence requirements of therapies in a real-
world setting
21
. 
 
 
 
 
 
 
   
19 
 
Table 3. Variable activities supported by RWD across the product lifecycle
23
. 
Preclinical Phase I-II Phase III Peri-Launch Phase IV 
Marketing 
Sizing 
Market Landscape 
Competitor 
Reconnaissance 
Registries Safety Surveillance 
Unmet Need Economic Burden Patient Burden 
Target Product 
Profile 
Continuous 
Monitoring 
Patient Profiling Disease History Treatment Patterns Labelled Claims Tailored Therapeutics 
Early Modelling Model Refinements 
Endpoint 
Assessment 
Global Value 
Dossiers 
Health Technology 
Assessments 
 
Endpoint 
Development 
Piggyback 
Evaluations 
Pricing &  
Reimbursement 
New Indications 
 
Instrument 
Validation 
  
Comparative 
Effectiveness 
    
Risk Sharing 
Arrangements 
 
In the view of many analysts and researchers, RWD has significant potential to improve 
the ways drugs are discovered and developed (Figure 6)
8
. In Portugal, there is no 
structured RWD collection still, but in framework of Decree-Law nr. 97/2015 of 1
st
 June 
and implementation of national HTA agency, are being discussed the utility of registries 
and the use of RWD to access the outcomes of interventions
24
. 
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Figure 6. Examples of RWE applications in some countries
25
. 
 
The main driver behind the development of an EU-level approach to RWD appears to be 
the European Commission’s push for the development of eHealth infrastructures and use 
of EHR. The European Commission has been particularly active in the development of 
methodological standards to facilitate the collection and use of patient data. The 
European Health Strategy for the 2008–2013 programming period has put emphasis on 
the development of eHealth infrastructures and on the funding of research projects 
aiming to promote the adoption of international terminology and coding standards to 
enable data sharing and international comparisons
8
. 
 
 eHealth infrastructures: 
The term “eHealth” describes the “application of Internet and other related technologies 
in the healthcare industry to improve the access, efficiency, effectiveness, and quality of 
clinical and business processes utilized by healthcare organizations, practitioners, 
patients, and consumers in an effort to improve the health status of patients”. eHealth 
comprises institutional structures, data architecture systems, competence centres and 
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legal frameworks. Competencies of eHealth authorities cover a range of eHealth 
instruments, including ePrescriptions, telehealth and patients EHRs system
8
. 
 
 Electronic health records: 
An EHR is the longitudinal electronic record of an individual patient that contains or 
virtually links records together from multiple Electronic Medical Records (EMRs) which 
can then be shared across health care settings (interoperable). It aims to contain a history 
of contact with the health care system for individual patients from multiple organisations 
that deliver care
8
. 
Another important driver is the increased support for the development of EU-wide 
datasets and enhanced interoperability. Enhancing interoperability between European 
datasets constitutes part of the Strategy objectives. Cross-country research projects are 
actively supported by different EU programmes to link existing registries, develop new 
ones and pool resources, paving the way to more standardised strategies for the 
collection and use of RWD. These recent developments are creating new opportunities 
for research through improved data collection and enhanced interoperability; however 
they remain quite fragmented, potentially hindering the pace of scientific advances. 
Reflexions on data harmonisation, data linkage and interoperability are therefore taking 
place at the European level, aiming to give guidance on data harmonisation
8
. 
 
5.1 REAL-WORLD DATA  TO BUILDING EVIDENCE FOR DRUG DEVELOPMENT AND POST-MARKET 
STUDIES 
 
5.1.1 DRUG DEVELOPMENT  
RCTs have traditionally been the preferred setting for product development in the 
healthcare industry. As was discussed above, RWD can also be used to assess the efficacy 
of different medical treatments and inform drug development strategies. For instance, a 
research team including researchers directly affiliated with GSK and Novartis studied the 
relative efficacy of drugs used to treat Chronic Obstructive Pulmonary Disease (COPD) and 
the relationship between these data and the results of clinical trials, using data from the 
Optimum Patient Care Research Database. Another study sponsored by Novartis and 
called the European Cubicin Outcomes Registry and Experience project (EU-CORESM), is 
gaining access to a registry that gathers data from 118 institutions. The study considers 
the characteristics of the patient population and the relative efficacy of treatment for skin 
and soft tissue infections. The findings will also be used by the company for in-house 
research, going beyond the scope of the EU-CORESM study
8,26,27
. 
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Case Study 
- The Salford Lung Study 
The Salford Lung Study is the world’s first phase III pragmatic RCT in asthma and COPD, 
which aims to randomise over 7000 patients.  
Patients are randomised to receive either a continuation of their usual treatment or a 
novel once-daily DPI containing a combination of a new inhaled steroid and a new LABA 
(fluticasone furoate/vilanterol (FF/VI; GlaxoSmithKline, Stockley Park, UK)) for 12 months. 
After randomisation, patients receive “usual” care for 12 months by their own general 
practitioner (GP), practice nurse and community pharmacist. Effectiveness and safety 
data are monitored and collected in near-real time using an electronic health record, 
minimising the number of patient visits required. 
GPs prescribe as usual, patients order and collect repeat prescriptions in their usual way, 
and collect their study medication from their usual community pharmacist, which allows 
assessment of real-world medication adherence in terms of number of prescriptions 
delivered to the pharmacy and the number dispensed to the patient. 
There are yet no study results but the researchers believe that the creation of an 
effectiveness study environment in Salford serves as a benchmark for other initiatives, 
including pharmacovigilance and phase IV studies, to collate data from primary and 
secondary care. They anticipate that initiatives such as this will reshape the future of 
clinical trials and meet the demand for value-based medical evidence
20
.   
 
5.1.2 LONG-TERM OUTCOMES OF AN INTERVENTION 
 
Case study 
An example of medium-scale project using a disease-specific database can be found in a 
study using data from 870 patients to assess long-term outcomes of transcatether aortic 
valve interventions (TAVIs) based on the UK TAVI registry, which has been set up to 
capture the outcomes of all such procedures executed in the UK. The study, one of the 
first of its kind to concentrate on a mid-to long-term time horizon, tracked survival and 
mortality rates for the interventions at 30 days, 1 year and 2 years after the event. 
It found that while a substantive proportion of these high-risk patients were deceased 
within the first year, overall the survival rates were encouraging
8,28
. 
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5.1.3 PHARMACOVIGILANCE 
The European Union (EU) put forth a new legislation on pharmacovigilance in July 2012. 
The legislation has the overall objective to improve the safety of use of medicines in 
Europe and through a more proactive approach to risk minimization planning and post-
marketing follow-up
28,29
. Table 4 shows examples of risk management plans as suggested 
by European Medicines Agency (EMA) to ascertain and evaluate benefit and risk of 
specific treatment, treatment specific characteristics and the information needed to 
address a specific study question21. 
 
Table 4. Risk management plans to ascertain and evaluate benefit and risk
21
. 
Type* Main characteristics Potential study aims 
Information needed for 
analysis 
I.Passive surveillance 
Spontaneous reports 
received throughout the 
world (WHO, FDA AERS, 
etc.), routine PV 
Signal generation 
Number of reported 
adverse events (AEs) 
II. Stimulated reporting (“Dear Doctor letter. . .”)  Evaluation of safety signal Number of reported AEs 
III. Active surveillance 
– Sentinel sites 
– Drug event monitoring 
– Registry 
Evaluation of safety signal 
Safety and effectiveness 
study** 
Safety outcome, 
treatment, appropriate 
confounders 
Disease outcome, 
treatment, appropriate 
confounders 
IV. Comparative 
observational studies 
– Cross-sectional survey 
– Case-control study 
– Cohort study 
Evaluation of safety signal 
Effectiveness study on 
population level (RWE)** 
Safety outcome, 
treatment, appropriate 
confounders 
Disease-outcome, 
treatment, appropriate 
confounders 
V. Target clinical 
investigation 
– Large simple trial 
Safety and effectiveness 
study** 
Disease outcome, safety 
outcomes, treatment, 
appropriate confounders 
VI. Descriptive studies 
– Cross-sectional survey 
– Case-control study  
– Cohort study 
– Natural history of 
disease 
– Safety study  
– Drug utilization study 
Disease outcome, 
appropriate confounders 
Treatment, severity of 
disease, age and gender, 
etc. 
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*Source: Guideline on Risk Management Systems for Medicinal Products for Human Use. EMEA, 2005 
**Depending on design issues and information collected. 
Bold indicates potential sources of RWE. 
 
The new legislation puts a wider focus on continuous follow-up of both safety aspects as 
well as effectiveness from use in clinical practice spurring comparative effectiveness 
research. It involves stronger requirements on measuring the effectiveness of risk-
minimization plans for the most important risks associated with new medicines. In 
parallel, the benefit/risk assessment (B/R) section of periodic safety update reports 
(PSUR) and risk management plans (RMPs) was also re-examined, which allowing more in-
depth assessment of medicinal product B/R
28,29
. 
Each company has a system in place to collect and evaluate spontaneous reports of 
suspected adverse drug reactions (ADR). However, the spontaneous reporting system 
allows only the generation of safety signals and indicates where possible safety issues 
might be without quantification of the risk. Other data sources are needed to evaluate 
and validate such a signal further. The ADR system works well for rare and severe adverse 
events, but less for common morbidities. ADRs are usually underreported by primary care 
physicians and their ascertainment is also not done according to standardized criteria and 
therefore relatively subjective and imprecise. In addition, the estimation of reporting rate 
is usually not possible because the denominator (population exposed) is unknown und 
therefore relative safety cannot be assessed with any validity
21
.  
The new legislation had already spurred a new range of research, most specifically with 
respect to the obligatory post-authorisation follow-up studies (e.g. Post-Authorisation 
Safety Studies [PASS]). PASSs can either be clinical trials or non-interventional studies; 
they are any study relating to an authorised medicinal product conducted with the aim of 
identifying, characterising or quantifying a safety hazard, confirming the safety profile of 
the medicinal product, or of measuring the effectiveness of risk-management measures. 
PASS studies have certainly been carried out before, but with the mandatory assessment 
post marketing has created a wealth of new research activity in the area and search for 
credible data sources to respond to the new requirements
29
. These developments in 
tandem result in a clear shift towards continuous assessment of benefit as well as risk 
after a product is on the market in Europe. Sources of good quality RWD are essential for 
companies to meet regulatory authority expectations
28
. 
 
Case Studies 
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Several of the cases examined are concerned with post-market drug risk assessment. 
Such cases have used RWD to gain an in-depth understanding of specific issues, including 
the long-term effects of different treatment options on a determined patient group, such 
as those registered in a disease-specific registry
8
. 
It was also identified occasions in which studies have drawn on large national datasets to 
assess the impact of drugs or medical treatments. These included a Danish study that 
evaluated the net clinical benefit of new oral anticoagulants versus no treatment in a 
“real-world” atrial fibrillation (AF) population. The study used a long-term database 
covering all Danish patients discharged with AF over ten years (between 1997 and 2008), 
looking at patients’ clinical histories, including pharmacotherapy, and premorbid risk 
stratification scores for stroke/thromboembolism. The analysis was further facilitated by 
linking the existing dataset to the unique personal identifier and Danish biobanks in order 
to assess the effects of three drugs compared to usual treatment and inform healthcare 
decision making. Studies at the national level can, then, draw on databases linked across 
multiple identifiers and databases (depending on the maturity of the e-infrastructure of 
the individual countries)
8,30
. 
There are also examples of cross-border initiatives offering added dimensions by 
including a cross-national set of patients. The studies building on the EU-ADR database for 
example used eight databases in four European Countries (Denmark, Italy, Netherlands 
and the UK) where both clinical information and drug prescriptions are recorded for 
large-scale drug safety monitoring. The database contains information about 30 million 
patients. The studies looked at drug safety across a range of diseases including acute 
myocardial infarction; acute renal failure; anaphylactic shock; bullous eruption; and 
rhabdomyolysis
7,31
. 
A further example is supplied by the VAESCO (Vaccine Adverse Event Surveillance and 
Communication) project which has supported studies in the areas of vaccine safety 
surveillance. This study involved seven databases from European countries (Italy, Spain, 
Finland, UK, Sweden, Norway, Denmark and the Netherlands), covering at least 26.67 
million patients. Its aim was the development of vaccine safety and best practices, 
evaluation of strategies and new methods and to facilitate data collection through 
common aims and standards, and to provide information on vaccination safety
8
. 
 
5.2 REAL-WORLD DATA  IN HEALTHCARE SERVICE DELIVERY 
 
Healthcare delivery decisions at the individual and system levels increasingly incorporate 
evidence from data analytics. RWD can be used to support personalised decisions on 
treatment options. These options are then tailored to the patient’s specific genotypic 
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characteristics and outcome probabilities. In other examples, data are incorporated into 
studies investigating questions related to health services coverage, quality or costs with a 
view to informing national or regional healthcare delivery strategies
8
. 
 
5.2.1 REAL-WORLD DATA FOR ASSISTING DOCTORS AND PATIENTS IN CHOOSING BETWEEN 
TREATMENT OPTIONS 
In some cases RWD and big data analytics are synthesised for initiatives involving 
personalised medicine and which require treatment decisions to be based on the 
individual characteristics of the patient. These cases use large datasets on treatment 
outcomes
8
.  
Case studies 
The EuResist project is an integrated European system for computer-based clinical 
management of antiretroviral drug resistance. Algorithms processing genotypic 
information across a multinational database are used with other genetic and response 
indicators in order to determine the best course of treatment for individuals with HIV 
infection. The initiative aims to develop a system capable of predicting how patients are 
likely to respond to a specific method of treatment and consequently recommend a 
certain treatment out of a portfolio of options. In pursuit of this aim, the project builds on 
databases of genotypic information, which are combined with data on drug resistance
8,32
. 
 
5.2.2 ANALYSING REAL-WORLD DATA  TO OPTIMISE THE EFFICIENCY OF HEALTHCARE SERVICES 
DELIVERY 
RWD analytics are particularly useful in supporting innovative ways to improve and 
optimise healthcare delivery.  
Case studies 
One potential area for innovation is that of expanding the potential range of healthcare 
services by aggregating data for decision-support and supporting telemedicine, as 
illustrated by the strategy for home care implemented in Southern Denmark. In this case, 
the new system was set up with the aim of improving outcomes for chronically ill 
patients. The strategy includes linking data across healthcare databases to create a 
holistic view of each patient; but also creates a platform that can integrate data from 
home monitoring and telemedicine applications and offer access to different healthcare 
professionals that can use the data to support their decisions. Furthermore, the 
automation of processes supports trends toward process optimisation and an efficient 
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use of time, while the business intelligence and analysis potential of the linked database 
may offer commercial value to the region
8
. 
In other cases RWD analytics has been leveraged to optimise current processes in 
healthcare delivery and limit associated costs, for instance by reducing the number of UK 
patients that have to be readmitted to hospital with Chronic Obstructive Pulmonary 
Disease (COPD) following their discharge. In this case, the computing assets of the 
National Health Service (NHS) enabled the analysis of multiple types of standardised 
patient and treatment data. The analysis supported the optimisation of the treatment 
process for patient outcomes and cost implications for hospitals
8
.  
Studies assessing healthcare delivery also include research investigating the evidence on 
the uptake of existing services and their delivery, for instance the effect of uptake of 
cardiac rehabilitation (CR) treatments on survival. Working with the database hold by 
private insurance Achmea, Van Engen et al. (2013) looked at this relationship in the 
Netherlands, and were able to demonstrate that despite the efficacy of the CR treatment, 
most Dutch patients did not receive this type of care
8,33
. 
Furthermore, the data analytics allowed the researchers to make recommendations 
about populations that should be specifically targeted by CR treatment initiatives, such as 
women, patients with long travelling distances to the nearest CR provider and patients 
with comorbidities
8
. 
RWD has also supported studies focusing on evaluating the quality of care. Franzke et al. 
(2009) collected data on patients with acne. This research allowed the capture of raw 
data and aspects of subjective patient experience and socioeconomic factors reported by 
patients with acne vulgaris. The data were then used to analyse the patients’ trade-offs in 
choosing between doctor prescribed medication and the acquisition of medical products 
through self-medication
8,34
. 
An example of a Portuguese registry to optimise the efficiency of healthcare services 
delivery, is the Reuma.pt (Rheumatic Diseases Portuguese Register), which includes 
patients with rheumatoid arthritis(RA), ankylosing spondylitis(AS), psoriatic arthritis(PsA), 
juvenile idiopathic arthritis(JIA), systemic lupus erythematosus and several other 
rheumatic diseases. The ultimate goal is to register all rheumatic patients treated with 
biological agents in mainland Portugal, Madeira and the Azores, ensuring effective 
monitoring of treatment indication, efficacy and safety. The Reuma.pt is also registering 
comparative cohorts of patients with RA, AS, PsA and JIA treated with classical 
immunomodulatory agents
35
. 
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5.2.3 ASSESSING THE COST-EFFECTIVENESS OF MEDICAL TREATMENT USING REAL-WORLD DATA  
RWD is also being used to inform decisions related to the burden of medical treatment 
costs. For example, the databases maintained in the Swedish national and Italian regional 
healthcare systems have been used to assess the burden of costs related to cardiac 
diseases or cancer (e.g. Lothgren et al., 2013; Roggeri et al., 2013)
8,36,37
.  
 
 
Case Studies 
Lothgren et al. (2013) have simulated cost implications per patient and examined the 
budget implications of different drugs used by patients with bone tumours. While the 
researchers could not directly access the relevant data, they triangulated available 
sources to estimate cost burden per patient and at the system level in Austria, Sweden 
and Switzerland. They thereby determined the drug with the lowest administration and 
collateral costs
30
.  
Roggeri et al. (2013) used a set of Italian regional databases (administrative databases of 
seven local healthcare units located in four different regions: Veneto, Toscana, Abruzzo 
and Puglia), linked with socio-economic datasets to assess the direct healthcare costs and 
resource needs associated with acute coronary events. Included in the study was 
information on demographic characteristics, prescriptions of drugs reimbursed by the 
national health system, hospital discharge records, outpatient visits and diagnostic-
therapeutic procedures
31
. 
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6. USE OF REAL-WORLD DATA  AND REAL-WORLD EVIDENCE IN EUROPE: STATE OF THE ART 
 
The European economy is still undergoing its worst economic health crisis in years and 
while governments are undertaking measures to foster growth after the financial crisis, 
regulators and payers are raising their requirements in order to ensure safe, effective, 
cost-effective and affordable medicines to its population. The focus during these past 
years has been on affordability and Europe has been forced to make tough decisions in its 
health care sector. A number of reforms have been initiated and implemented to try to 
improve on public efficiency such as health care delivery. These reforms, combined with a 
greater cost-consciousness amongst payers, have driven an increased requirement of 
RWE to better understand the consequences of the introduction of new medicines into 
the European markets
29
. 
RWD collection and use for reimbursement activities, such as relative effectiveness 
assessment, risk-sharing agreements and pharmacoeconomic analysis was the most 
noted actual context
1,34,38
. As payers demand for knowledge on drug utilization studies, 
real-life safety and clinical effectiveness to inform payment decision increases, so does 
the need for RWD. This evidence, in turn, helps payers to “better understand the 
outcomes of various treatments and only pay for those which are most beneficial to 
society”
1,39
.  
The second most recurring actual context for RWD collection and use was for regulatory 
activities. The theme most frequently mentioned within this context relates to the role of 
RWD in fulfilling post-marketing commitments. For example, RWS can be designed to 
collect information on long-term safety and effectiveness as part of phase IV, post-
marketing safety and pharmacovigilance commitments
1,29
.  
Collection and use of RWD during drug development was the third most-mentioned 
actual context. RWD is used, amongst other things, to help drug developers study the 
natural history of disease, define patient populations for clinical trials, standardize 
outcome measurements, define sub-populations for treatment, understand treatment 
patterns both pre- and at product launch, and, as previously-stated, long-term safety and 
effectiveness outcomes
1
. 
Another context that received equal mention was the use of RWD in drug utilization 
studies to investigate, for example, drug dosing in clinical practice, patient compliance, 
standard of care and treatment flows in different clinical contexts
1,29
. 
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6.1 REAL-WORLD DATA IN HEALTH CARE DECISIONS 
 
Decisions about the deployment of health resources are taken by 2 subjects: by 
physicians for the individual patient and by public health policy makers on a population 
level (governments, national health insurance providers and payers)
40,41
. Healthcare 
decisions preferably should be evidence-based and/or evaluated but reality shows that 
many decisions need to be taken on the basis of imperfect evidence and with uncertainty 
about the outcome of decisions. Evidence about the real-world can best be obtained from 
the real-world practice
40
. The use of RWD to monitor safety, measure outcomes and 
assess comparative effectiveness is increasing by healthcare provider, health plan and 
regulatory agency decision makers across the healthcare continuum
32
. 
In general terms, the policies on RWD collection and use differ per stakeholder group, in 
part due to the different goals/mandate such stakeholders groups have
1
. Payers must 
balance the need to provide improved health outcomes and access to new technologies 
with budgetary considerations. Clinical trials developed for regulatory purposes may be 
insufficient to resolve payer uncertainty. To physicians/researchers: techniques and tools 
to analyse data for RWE have become increasingly widespread and accessible to 
physicians. Physicians are now able to answer an increasing number of important health 
services and policy questions without the considerable expense, length of time, and 
complication of conducting high-cost experimental studies. Industry views RWD collection 
as an additional opportunity to demonstrate the value of medicines, for both the patient 
and the health system. It may also provide new opportunities for industry to work with 
payers to advance novel approaches to pricing and reimbursement
15
. 
Payers and HTA bodies believe that traditional approach of the drug development plan is 
deficient in that it is no longer sufficient to know if a new drug or technology is 
efficacious; the nature of the global healthcare marketplace means that it is essential to 
know how it performs in networks, communities, countries and populations as well as 
when it should be used and why it may be preferred to other treatments
33
. 
Traditionally, RWD has been collected prospectively in Europe by recruiting patients 
and/or health care providers to respond to specific sets of questions. In an era where 
there is the interest to interfere as little as possible when collecting health information 
from real-world health care practice, other ways of generating the evidence are being 
further. With an increased demand for RWD by multiple stakeholders, and a demand to 
generate critical evidence within a shorter time-frame and at a more cost-effective 
manner, retrospective data collection has become a more attractive form of generating 
RWE. Europe as a region has substantial potential to become an important area for this 
type of research activities with a long history of collecting patient-level data
29
. 
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For more sophisticated RWD, linked patient-level data representing entire populations 
and their complete care flow throughout the health care system is more and more 
critical. In the UK, the Ministry of Health, together with the EMA did an important effort 
to pave the way for one important data source widely used today. The Clinical Practice 
Research Datalink (CPRD) is a database developed through linkage of patient-level data 
from various parts of the NHS health care system into one entire database. CPRD has 
managed to set up a system providing access to its data to all stakeholders by licensing 
the data under certain premises. By allowing for this transparency, CPRD has also become 
scrutinized by many researchers and hence accepted by most parties
29
. 
A region where there are great opportunities for more advanced RWD generation is the 
Nordic region. All Nordic countries have national and population-based health registers in 
place since the 1950’s to which there is mandatory reporting of patient-level information. 
Some key strengths with these data sources are that they represent the entire population 
of 25 million inhabitants in the region, different data sources can be linked at an 
individual patient-level through unique patient identifiers and that the data are very rich 
and longitudinal. Moreover, given the greater focus on patient outcomes and 
personalized medicine, the Nordic region has universally adopted EMR in its health care 
systems as a result of decades of providing a strong source for RWE
29
. 
Some European countries have various great regional data sources, others are developing 
systems that allow for continuous access and use of rich patient-level data, in some these 
cases regulators and HTA agencies already using RWD to decision-making
25,29
. To highlight 
markets’ individual characteristics, imshealth
®
 created an RWE assessment scale based on 
supply and demand. Data supply and demand frameworks were each scored out of five 
and application was scored out of ten to reflect the importance of observing RWE 
demand in practice. This reveals major differences in RWE impact, with countries scoring 
between 2 and 11 of a potential 20 (Figure 7). The maximum score of 11 reflects that no 
country has the ideal conditions for RWE use in a scalable manner and highlights RWE’s 
infancy. Lower scores indicate that RWE is relatively less available or more costly to 
generate with less consistent or transparent use in decision making. But even in markets 
with lower scores, RWE is still relevant
25
. 
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Figure 7. RWE market impact scores (out of 20)
25
. 
 
UK is closest to the ideal because RWE is used in systematic review for most evaluation 
processes (HTA, reimbursement, clinical guidelines). Stakeholders can disseminate RWE 
directly to prescribers, and RWE-enabled payment-for-performance contracts encourage 
appropriate prescribing. Even the UK can go further: for example, RWE-enabled 
prescribing indicators are still limited. Conversely, countries like Denmark and Spain lack 
clearly defined roles for RWE in decision frameworks
25
.  
In terms of application – where RWE has informed decisions – all countries are distant 
from the ideal. Consistent, transparent use of RWE in decision making is lacking across 
therapeutic areas and patient populations. Case studies from the UK suggest the most 
extensive application, given the number, variety, and breadth of resulting decisions 
relative to the entire health system. Conversely, in countries such as Germany, public case 
studies of RWE application are rare
25
.  
Combining the strengths in frameworks and application with strong patient-level 
databases, the UK becomes the highest scoring market. In the UK primary care datasets 
are long-standing and high quality, supporting over 1,000 peer-reviewed research papers. 
These are being transformed into a wider linked dataset, the CPRD under government 
leadership
25
.  
Spain ranked last based on lack of patient-level data and RWE use outside of a few 
specific regions. Spain has regional pockets of extensive electronic data capture but the 
lack of translation into research datasets limits its ability to generate RWE. National HTA 
approaches are under development but have yet to explicitly address RWE use in 
evaluation. Different case studies of RWE use could be identified at the regional level 
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particularly in relation to access, though the extent to which medicine use was really 
impacted was limited
25
. 
Data presented by Lilly (2014) showed that Portugal has in Europe tail of RWD availability 
(Figure 8); in contrast, France, Italy, Netherland, Belgium and Nordics  have a good 
integrated RWD collection and stakeholders considered RWE an essential tool
35
. 
 
Figure 8. Availability of RWD
35
 . 
We are just in the beginning of a new era for Europe to thrive its opportunity to make use 
of data sources available across the region. 
 
6.1.1 IMPLICATIONS IN ASSESSMENT OF THERAPEUTIC VALUE 
 
The therapeutic value can be defined in terms of positive patient-relevant endpoints and 
relevant levels of effectiveness, efficacy and safety
17
. Knowledge of the therapeutic value 
brought a new drug is a core element supporting treatment decisions. By comparing a 
new drug with the best available treatment option, it can be deemed an added 
therapeutic value if it demonstrate a relevant level of therapeutic advantages
17,42
.  
Among different stakeholders, perceptions of the value of a medicine may differ in terms 
of evidentiary criteria needed for adoption. Patients are likely to value a medicine that 
prevent or slow the progression of disease or those that can demonstrably improve QoL 
by alleviating symptoms. For physicians, value could be perceived as “moving the needle” 
on some clinical surrogate endpoint with which they are familiar. For example, a specific 
change in mmHg systolic blood pressure or a particular change in haemoglobin A1C may 
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be sufficient for clinicians to feel a new treatment is worthwhile. But for payers, the 
definition of value is somewhat elusive and differs across/within countries
33
.   
According European Parliament's Committee on Environment, Public Health and Food 
Safety, the main tools used to estimate added therapeutic value (ATV) is Relative 
Efficacy/Effectiveness Assessments (REA)
17
. REA is the extent to which an intervention 
does more good than harm, under ideal circumstances, compared to one or more 
alternative interventions. The High Level Pharmaceutical Forum investigated the data 
availability to conduct relative effectiveness assessments. It was concluded that there is 
no clear consensus as to whether clinical trials yield efficacy or effectiveness information. 
All data on pharmaceuticals yield information that is somewhere on an 
efficacy/effectiveness spectrum, as illustrated in Figure 9 which is a simplified 
presentation of the spectrum. As a general rule, conventional clinical trials tend more to 
the efficacy side of the spectrum. The term effectiveness is used differently in EU 
Member States, which does not correspond with the High Level Pharmaceutical Forum 
definition. While some Member States use it to describe what is actually happening in 
real-life (which is always theoretical to a certain extent), others stated to use it exclusively 
to describe clinical trials that are as far as possible to the effectiveness side of the 
spectrum. According to these Member States, this gives the best estimate of what 
happens in real-life. There is no clear consensus on the interpretation among EU Member 
States
43
. 
Figure 9. Efficacy/effectiveness spectrum
43
. 
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The added therapeutic value of new medicinal products can be assessed at different 
stages during the manufacturing and distribution processes. In broad terms, there are 
two important moments when the clinical assessment can play a role: prior to the 
authorized entry of the medicine onto the market (marketing authorisation phase); and 
when the pricing of a new medicine and its reimbursement is determined (pricing and 
reimbursement phase)
17
. 
In practice however, the ATV assessments (through REA) are often conducted at the stage 
of pricing and reimbursement of the medicine, rather than prior to its authorised entry 
onto the market 
17
.  
It acknowledged that differences between the objectives and priorities of different 
national health care systems may create differences in the way in which health-care 
interventions will be evaluated relative to one another and differences in relative 
effectiveness valued. In a survey of 27 member states in 2007, however, it was found that 
little distinction is currently made in member state assessments between efficacy and 
effectiveness. Member states mostly relied on relative efficacy data to inform their HTA 
and felt that there was inadequate effectiveness data available
38
. The ATV is not the only 
aspect considered by national authorities when assessing new medicines: its cost, 
budgetary impact and the quality of evidence used for the ATV assessment are also 
important considerations. A multi-disciplinary assessment that is often used and referred 
to is HTA, which encompasses a systematic evaluation of the wider aspects and issues 
related to the introduction of a new medicine or drug. HTA is conducted by 
interdisciplinary groups using analytical frameworks drawing on a variety of methods, 
with the main purpose of informing technology related policymaking in health care. The 
REA and ATV remain the central element of HTA, but cost-effectiveness in particular is 
seen as an important element to complement the REA
17
. 
HTA agencies generally refer to a comprehensive evidence base that combines data from 
several sources when assessing the clinical effectiveness of health interventions. 
Therefore, non-RCT evidence is also considered when performing health technology 
assessments
1
. Recently, the conducting of pragmatic RCTs within EHR databases providing 
an assessment of the comparative effectiveness in a randomised method. Patients are 
recruited at the point of care, randomised among routinely available interventions and 
then followed unobtrusively using the electronic health care database. The EHR database 
can be used to identify patients with criteria of inclusion. After eligibility review by the 
clinician and informed consent, patients are then randomised. Study participants are then 
followed for treatment and for major clinical outcomes using the EHR data. The 
randomisation ensures that baseline differences and confounding is reduced
44
. 
Moreover, in instances when there are uncertainties regarding the safety and 
effectiveness of new medications, additional RWD may be requested at the time of initial 
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reimbursement which would need to be collected within an agreed-upon time period. 
The collected RWD would then be used for reassessment of clinical effectiveness at the 
end of this period. These arrangements are often classified as Market Access Agreements 
(MAA’s), Coverage with Evidence Development (CED) schemes, or Payment for 
Performance (P4P) schemes
1
. 
Several HTA agencies adhere to a hierarchy of evidence that places non-RCT data, such as 
observational studies data, at a lower level than RCT data. As a result, RWD is regarded as 
inherently being of lower quality thus conclusions made based on RWE are regarded as 
more circumspect. Clinical effectiveness is thus rarely solely determined on the basis of 
RWE. Causality is also not determined on the basis of RWE. Nonetheless, it has been 
noted in several documents that collection and use of RWD allows for timely generation 
of valuable evidence. In fact, the use of automated outpatient pharmacy data, electronic 
health records by physicians, and applications on smartphones by patients, can provide 
real-time health data. This significantly reduces the time needed to gather sufficient RWD 
for relative effectiveness studies. Moreover, several authors mentioned that the use of 
EHR, pragmatic clinical trials, claims databases and existing patient registries for RWD 
generation is more cost-effective in comparison to setting up RCT’s. For example, the 
European Alliance for Personalised Medicine refer to the company Handle my Health 
which has the ability to aggregate patient data from multiple health smartphone 
applications (“apps”) into one data packet before sending it to the MHRA in the United 
Kingdom for real-time verification of data, potentially in the context of early access to 
medicines schemes. Another example concerns the recently-published findings of a RWS 
by PatientsLikeMe, demonstrating that lithium did not affect amyotrophic lateral 
sclerosis. RWD for this study was self-generated by patients of the PatientsLikeMe 
community and preliminary results were published in peer-reviewed journal after only 9 
months from study initiation
1
. 
It is important to note that all guidelines provided by HTA agencies does not dictate what 
sort of RWD data should be collected, the RWS design, the data collection tools to be 
used, or the statistical analysis methods to be used
1
. Some of these guidelines stated that 
RWE is a “nice to have” as a supplement for evidence in economic evaluations, but is not 
required. More specifically, they acknowledged the usefulness of RWD in: 
- Sourcing country-specific resource use and costs; 
- Estimating natural history and baseline risks in actual clinical practice, therefore 
supporting the extrapolation of RCT data and facilitating modelling beyond the time 
horizon of the RCT; 
- Sourcing country-specific QoL data; 
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- Estimating long-term outcomes, especially treatment-related (i.e. true effectiveness and 
safety); 
- Sourcing true compliance estimates; 
- Identifying real-world treatment pathways and comparators; 
- Providing evidence for a patient population that is broader than that of the RCT, hence 
enhancing the generalizability and transferability of the results (e.g. patient with co-
morbidities or concomitant therapies); 
- Further validating model assumptions and performance in a real-world setting
45
. 
Even so, in recent years has been an increasing interest in incorporating RWD/RWE in 
HTA. One of these examples are presenting below. 
 
Case study 
Inclusion of RWE in HTA 
“Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of 
osteoporotic vertebral fractures: a systematic review and cost-effectiveness analysis”
46,47
. 
Percutaneous vertebroplasty (PVP) is a minimally invasive surgical procedure in which 
bone cement is injected into a fractured vertebra. Percutaneous balloon kyphoplasty 
(BKP) is a variation of this approach, in which an inflatable balloon tamp is placed in the 
collapsed vertebra prior to cement injection. 
The objective of this review was to systematically evaluate and appraise the clinical 
effectiveness and cost-effectiveness of PVP and BKP in reducing pain and disability in 
people with osteoporotic vertebral compression fracture (VCFs) in England and Wales.  
Results showed that for people with painful osteoporotic VCFs refractory to analgesic 
treatment, PVP and BKP perform significantly better in unblinded trials than optimal pain 
management (OPM) in terms of improving QoL and reducing pain and disability. However, 
there was as yet no convincing evidence that either procedure performs better than 
operative placebo with local anaesthetic (OPLA) with data from two high-quality trials. It 
can be argued that these procedures should not be undertaken unless the patient has 
failed to respond to a facet joint injection.  
It is possible that BKP and PVP may lead to reductions in mortality and at different levels 
of effect; however, this possibility was derived from registry data (from USA and 
Germany) and without information on the causes of death in these cohorts, and in the 
absence of randomisation, it was not possible to conclusively establish a causal link. There 
were no data to analyse whether or not OPLA would also be associated with mortality 
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benefits. If such benefits exist then the cost per quality-adjusted life-year (QALY) gained 
of the interventions compared with OPM would be low. 
 
Some questions remains without answer: 
Can it use the observational data available from the US and Germany to estimate 
mortality differences between treatments for osteoporotic VCFs? 
Can it use bias adjustment methods to pool both randomised and observational (even 
after propensity adjustment) data on mortality?  
What impact do mortality differences have on the cost-effectiveness of PVP and BKP vs. 
non-invasive management? 
 
6.1.2 THE CHALLENGE OF OBTAINING REAL-WORLD EVIDENCE 
 
Although the potential of RWD use seems quite clear, it was revealed barriers that restrict 
further development towards its full exploitation: 
- the absence of common standards for defining the content and quality of RWD 
(absence of common terminology, incomplete datasets, lack of data quality 
assurance systems); 
- methodological barriers (absence of standards for RWD analysis and for data 
linkage) that may limit the potential benefits of RWD analysis; 
- privacy concerns expressed predominantly by clinicians and patients and binding 
data protection legislation which can be seen to restrict access and use of data; 
- governance issues underlying the absence of standards for collaboration between 
stakeholders active in the field of RWD, and limitations of incentives for data 
sharing
8
. 
The complexity of data collection underscores the fact that the level of evidence required 
in any circumstance will relate to the question at hand. It is important to recognize the 
variable quality of data (whether prospective or retrospective, or experimental or 
observational) and the expectations across regulators, payers, provides and patients
9,13
. 
This diversity arises because of differing priorities. Obtaining early insights into these 
needs is fundamental to design an efficient RWE strategy
14
. 
The challenge of meeting both regulatory and payer requirements is being recognized. 
Efforts are underway to streamline regulatory and payer processes and reduce the 
complexity. Two examples include the contribution of regulatory assessment reports to 
HTAs and initiatives to promote early dialogues: 
   
39 
 
1. The European network for Health Technology Assessment (EUnetHTA) initiated 
collaboration between the European regulator and HTA bodies with the aim to improve 
the contribution that regulatory assessment reports – the so-called European Public 
Assessment Reports (EPARs) - can make to the assessment of relative effectiveness of 
medicinal products by HTA bodies. As a result, the templates for preparing EPARs were 
revised to better address the needs of health technology organizations. Even the 
regulators and HTAs acknowledge that understanding a broad range of needs is crucial
14
. 
2. Shaping European Early Dialogues for health technologies (SEED) is an international 
project financed by the European Commission from October 2013 to August 2015. The 
SEED Consortium, led by the French National Authority for Health, is composed of 14 
European HTA agencies. The aim of the SEED project is to conduct pilots on early 
dialogues between its member HTA agencies and manufacturers of health technologies 
(pharmaceuticals and medical devices) whose products are currently in the development 
stage. In total, 10 early dialogues are planned, with seven focused on drugs and three on 
medical devices. Early dialogues allow companies developing health products to meet 
with European HTA agencies in order to present their development plan for the product 
in question, and to ask specific questions relative to their plan. The objective of the SEED 
early dialogues is to reduce the risk of production of data that would be inadequate to 
support the company’s future reimbursement request
13
. 
Prospective observational studies and interventional trials allow researchers greater 
control over the completeness and quality of RWD, but at increased time and cost. A 
recent phenomenon is the dramatic increase in the number of very large global 
prospective observational studies. Twenty-nine industry sponsored observational studies 
of over 5,000 patients were started in the period 2009-2011 compared with 65 in the 
period 2012-20143. Such “elephant” studies are indicative of sponsors’ recognition of the 
common questions across markets, the need for increased sample size for greater 
statistical study power, and more centralized decision-making to streamline real-world 
research programs
13
. 
 
6.1.3 LOOK INTO THE FUTURE 
 
The RWD activities are expected to increase by 25 % in the next years. Most of these 
activities are studies which have safety and effectiveness objectives and to a lesser extent 
drug utilization and health economics and the most common therapeutic areas are: 
oncology, cardiovascular and metabolic disorders. Pharmaceutical companies are 
conducting more and more epidemiological studies to prepare dossiers for market access 
(disease understanding, unmet needs, population targeting), it face big challenges for the 
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coming years especially in EU and there is an increase need for local regulatory 
knowledge. There’s still need to increase awareness for the importance of RWS and the 
impact it has on the patient’s life
48
.  
The issue of obtaining relative effectiveness data is highly recognized, and efforts are 
underway to find solutions. Several recent initiates, pilot programs and public-private 
partnerships to develop methods and systems for using RWD generated by the healthcare 
system had been established. For example the EU-based Innovative Medicine Initiative 
(IMI) program “GetReal”. It is a public private consortium consisting of pharmaceutical 
companies, academia, HTA agencies and regulators, patient organizations and subject 
matter experts. The goal of GetReal is to develop new ways of incorporating real-life 
clinical data into drug development. The benefits of this are manifold – not only will it 
help pharmaceutical companies take better decisions during drug development, it will aid 
healthcare decision makers when deciding how best to grant patients access to a new 
treatment
21,49
. 
Among other things, the project will analyse existing processes and methodologies for 
HTA. It will also generate a decision-making framework to help pharmaceutical companies 
design drug development strategies. The framework would include ideas for the design of 
trials and studies capable of providing information on the real world effectiveness of 
medicines, including relative effectiveness
49
. 
The project also aims to develop tools that will allow different stakeholders in drug 
development and approval to test different mathematical models in their decision making 
and assess their impact. It will create a network of regulators, HTA organisations, 
companies, academics, healthcare professionals, patients and other societal stakeholders. 
This is important because the challenges faced by the pharmaceutical industry, regulators 
and other healthcare decision makers are linked
49
. 
By bringing together all key stakeholder groups (namely industry, academia, regulatory 
agencies, HTA bodies, reimbursement agencies, healthcare budget holders, and patient 
groups) to share their insights and know-how, GetReal would help to generate a 
consensus on best practice in the timing, performance and use of real-life clinical studies 
in regulatory and reimbursement decision-making. It will also help to create a strong 
platform for the communication of results and for future discussions in this important 
area
49
. 
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7. CONCLUSIONS 
 
In the last years has been discussed the promise of RWD. A number of analysts and 
academics have signalled its potential to contribute to improved health products and 
outcomes. Advances in computing allow collecting, share, analyse and use large 
quantities of data routinely at a relatively low cost – as never before. The increased use of 
new technologies in the healthcare sector has changed the ways in which patient level 
information are collected, stored and used. In this context, RWD can be used in 
conjunction with RCTs and other medical data to provide insights into real-world clinical 
outcomes. RWS conventionally include a larger, broader study population than RCT’s, 
implying that they are sufficiently empowered to significantly capture heterogeneity of 
treatment effects in clinical practice. RWS are often conducted over a longer time horizon 
than RCT’s and as such their results can be more accurately extrapolated to future effects 
when compared to RCT results. The ability of RWD to address knowledge gaps presented 
by RCT-generated evidence was the also recognised as advantage. For example, 
pragmatic clinical trials by design can be used to identify drug-drug interactions, 
overdosing or other forms of inappropriate use of medications. RWE is also a valuable 
source of safety and effectiveness data in exceptional circumstances where RCT’s are not 
ethical (e.g. narcotic abuse) or feasible (e.g. for the urgent reimbursement of a novel 
medication to treat a life-threatening disease). In more general terms, the generalisability 
of results of RWE contributes to filling what has become to be known as the “efficacy-
effectiveness gap. RWD also allow for assessment of long-term effects and rare serious 
adverse effects, owing to the larger number of patients for whom data is conventionally 
available and the wider range of health outcomes measured when compared to 
RCT’s
1,8,9,50
. 
In fact, the use of automated outpatient pharmacy data, electronic health records by 
physicians, and applications on smartphones by patients, can provide real-time health 
data. This significantly reduces the time needed to gather sufficient RWD for relative 
effectiveness studies. Several authors mentioned that the use of electronic health 
records, pragmatic clinical trials, claims databases and existing patient registries for RWD 
generation is more cost-effective in comparison to setting up RCT’s
1
.  
It was also identified factors limiting the potential benefits driven from RWD analysis. The 
liability of RWD to different form of biases (i.e. selection bias, information bias and 
confounding bias) was the most recurring disadvantage. Retrospective or prospective 
observational or database studies do not meet the methodological rigor of RCTs, despite 
the availability of sophisticated statistical approaches to adjust for selection bias in 
observational data (covarate adjustment, propensity scores, instrumental variables, etc.). 
Observational studies need to be evaluated rigorously to identify sources of bias and 
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confounding, and adjusted for these prior to estimating the impact of interventions of 
health outcomes. Observational or database studies may also require substantial 
resources. Several of authors went on to indicate that, as a result of biases, the 
determination of causality based on RWD should be done with caution
1,9,21
.  
The poor quality of RWD available was too mentioned disadvantage. Incomplete or 
missing data was the specific disadvantage highlighted in relation to poor quality of RWD. 
This pertained to, among other things, databases with incomplete information (“gaps”) 
on certain collected elements, the absence of outcomes representing “mild” outcomes, or 
missing lab data. The phenomenon of incomplete data can be related to the type of 
healthcare database; for instance, claims databases inherently lack information on clinical 
disease severity and lifestyle habit. On the other hand, electronic healthcare records may 
also have data gaps on clinical outcomes or have incorrectly-coded medical diagnostic 
information. On a similar note, several authors have noted that despite the presence of 
many different sources of RWD, such as electronic healthcare records and administrative 
claims databases, the majority of these databases have not been established to collect 
information for research purposes. For example, EHRs capture data on symptomatic 
outcomes of interest, but have little information on mild symptoms. Researchers 
therefore need to remain aware of different types of data sources and their 
corresponding limitations when initiating RWS’s
1,8
. 
Another important disadvantage that received little mention is the availability of RWD 
and RWE at the time of important decision-points in the product lifecycle. For instance, at 
the stage of reimbursement, payers often require data on the real-world relative 
effectiveness of new interventions that is usually not yet available pharmaceutical 
industry
1
.  
The lack of standardization of RWD collection methods and definitions of terms, as well as 
the lack of harmonization (regionally and internationally) of required RWD data is 
frequently considered practical obstacle
1,8
.  
Another issue is the ambiguity regarding the applicability of RWE to decision-making. Due 
to several factors such as the lack of consensus among stakeholders on the value of RWE 
and lack of guidance on using RWE in decision-making, ambiguity remains on how RWE 
should be used decision-making processes. The recurrent political consideration of RWD 
refers to the need for increased collaboration among stakeholders on a number of issues. 
Firstly, it has stated that agreement must exist between HTA agencies and regulatory 
agencies as to evidence needs RWD should fulfil; phase IV, post-marketing studies 
conducted for regulatory purposes can provide very useful insights for questions on 
relative effectiveness relevant for reimbursement decisions. Therefore, more dialogue 
needs to take place on harmonizing data needs from these two stakeholder groups. 
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Secondly, it also states that key stakeholders (patients/ patient organizations, regulatory 
agencies, HTA agencies, pharmaceutical industry, payers/insurers and academia) should 
come together as co-designers of projects when identifying RWE needs and designing 
RWS’s
1,33
. 
 
In conclusion, the collection of RWD represents an important way forward to determine 
the value of medicines. However, for it to proceed in a comprehensive fashion, we need a 
reality check on several important methodological and practical issues. Detailed 
methodological guidance for the collection of RWD needs to be produced. Also HTA and 
regulatory agencies need to engage in more discussion about the types of data required 
and the decisions that will result
51
. 
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